Abstract
The therapeutic landscape of advanced prostate cancer has considerably broadened in recent years. With the implementation of sensitive functional imaging techniques, advanced prostate cancer is no longer limited to metastatic castrate-resistant disease, but now also includes metastatic hormone-sensitive prostate cancer and some localized tumors that have previously unrecognized occult met…